Further to our original notification of 1 October 2019 we have provided additional information of a possible alternative product below.

New information is shaded in grey.

Click here to read the GSK notification relating to the above mentioned product.

You must immediately complete and fax the acknowledgement form provided regardless of whether you have stock or not. This is a requirement under your current ICPSA .

NOTE: ProPharma /PWR will be processing credit returns and all credit returns must be accompanied by a copy of the acknowledgement form and the associated credit return form completed accordingly.

Please clearly identify any credit returns by packaging in a separate bag and clearly labelled as RECALL CREDIT.

Credits should be returned no later than 11 October 2019.

ProPharma /PWR have NO stock that is unaffected by the recall.

We are able to PROCURE an alternative under Section 29 as follows:-

Ranitidine (Alliance) Soln for Inj and Infusion 50 mg /2ml 5 x 2ml pack

Cost to pharmacy $31.68 + GST plus $3.00 Admin Fee.

Allow 2 weeks for procure.  Expiry date 06/2021.

Should you wish to order stock please do so via our procure process and note that all stock supplied will be on a non-returnable basis without exception.

We thank you in anticipation of your ongoing support.

About The Author